Parry Labs Names Scott DeVona CRO to Drive $100M-Proven Revenue Strategy
DeVona spent two decades building defense software businesses and winning software-centric programs for the
He joins Parry from Research Innovations, Inc., where he ran a commercial software organization and converted mission software into licensed products carrying recurring revenue for
DeVona began his career as a software engineer at Fort Monmouth, sitting in the Army program offices alongside the senior military leaders who shape requirements and make program decisions. He held progressively senior roles from there, advancing through technical program management into business development leadership, then into full profit and loss ownership. He has twice helped build a defense software company from an early team into an established provider, joining one as its seventh employee and the other as its first business development hire, where he built the corporate growth function from nothing and helped grow the company more than tenfold.
"Scott knows how to win programs, and he knows how to build a product business around the software that delivers them," said
"Programs are being asked to connect the systems they have today with the autonomous systems arriving tomorrow, and to do it without being locked into any one vendor," said
About Parry Labs
Parry Labs is a defense technology company headquartered in Alexandria, Virginia. Parry Labs creates vendor-independent interoperability across current and future mission systems, connecting and translating platforms, sensors, networks, AI, and mission data at the tactical edge without forcing customers into a proprietary ecosystem.
View original content to download multimedia:https://www.prnewswire.com/news-releases/parry-labs-names-scott-devona-cro-to-drive-100m-proven-revenue-strategy-302872398.html
SOURCE Parry Labs LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Invisors named one of the UK's Best Workplaces in Consulting and Professional Services™ 2026
- Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress
- The U.S. FDA grants orphan drug designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for treatment of endogenous Cushing's syndrome
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share